Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy
研究概览
地位
详细说明
PRIMARY OBJECTIVES:
I. Evaluate whether vaginal dilator adherence is improved with additional reminder phone calls and/or email reminder survey.
SECONDARY OBJECTIVES:
I. Evaluate whether there are differences in the length of vaginal canal between the non-intervention and intervention groups. Evaluate rates of gynecologic, urinary, and gastrointestinal toxicity.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive no additional reminders.
ARM II: Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
ARM III: Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
After completion of study, patients are followed up at 10-14 weeks, 5-7 months, 8-10 months, 11-13 months, 15-17 months, 19-21 months, and 23-25 months post treatment.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Stanford、California、美国、94305
- Stanford University, School of Medicine
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of their treatment
- Patients cannot have previously received pelvic external beam radiation or brachytherapy. Patients may be enrolled while undergoing vaginal brachytherapy radiation treatment.
- Patients should have a life expectancy of at least 1 year
- No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status requirements
- No organ and marrow function requirements
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have received prior pelvic external beam radiation or brachytherapy will be excluded
- No restrictions regarding use of other investigational agents
- No exclusion requirements due to co-morbid disease or intercurrent illness
- No investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device
- No exclusion criteria relating to concomitant medications
- No exclusion criteria for pregnant or nursing patients from participating in this study (Of note, pregnant patients will not be treated with vaginal brachytherapy, a requirement for enrolling on this study)
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:Arm I (no intervention)
Patients receive no additional reminders.
|
|
|
实验性的:Arm II (email survey)
Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
|
Receive reminder email survey
Receive reminder email survey
|
|
实验性的:Arm III (email surveys and phone calls)
Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
|
Receive reminder email survey
Receive reminder email survey
Receive reminder phone call
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Vaginal dilator adherence, measured by the average number of times per week patient uses a form of vaginal dilation
大体时间:Up to 25 months after completing radiation
|
The vaginal dilator adherence measurements will analyzed in repeated measures model with treatment as a fixed effect and time as a within subject effect.
The overall mean of vaginal dilator adherence among the 3 groups will also be measured and compared.
The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.
|
Up to 25 months after completing radiation
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Vaginal canal length
大体时间:Up to 25 months after completing radiation
|
The vaginal canal length will be measured using an extra small dilator and it will be calculated in centimeters.
The vaginal canal length measurements will be analyzed in a repeated measures model with treatment as a fixed effect and time as a within subject effect.
The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.
|
Up to 25 months after completing radiation
|
|
Incidence of adverse events (AE), reported by type and grade using the Common Terminology Criteria for Adverse Events version 4.03
大体时间:Up to 30 days after the last dose of study treatment
|
The adverse events will be tabulated by type and grade at each follow up.
The total number of AE's as well as the number of AE's in each category: gynecologic, urinary and gastrointestinal will tabulated.
The test of proportion will be done per category of AE.
Since it is possible that the rates will be low, an exact test will be used to compare the rates.
|
Up to 30 days after the last dose of study treatment
|
合作者和调查者
调查人员
- 首席研究员:Elizabeth Kidd、Stanford University Hospitals and Clinics
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.